Wonderful review｜A series of activities of the Lymphocytic Disease Group of the Hematology Branch of the Chinese Medical Association-the 2nd Bethune's Lymphoma Youth Forum in 2021

On the morning of May 29, 2021, a series of activities of the Lymphocytic Disease Group of the Hematology Branch of the Chinese Medical Association-the 2nd Bethune Lymphoma Youth Forum in 2021 was successfully held.

The conference was hosted by the Lymphoma Disease Group of the Hematology Branch of the Chinese Medical Association and organized by the Lymphoma Specialty Alliance of the First Hospital of Jilin University.

Many big names and young experts in the lymphoma field from all over the country conducted in-depth analysis and intense discussions on hot issues in the diagnosis and treatment of lymphoma.

The conference adopted an online live broadcast method, which attracted many workers in the lymphoma field.

Yimaitong organized the main highlights of the conference as follows.

Opening remarks At the beginning of the meeting, Professor Bai Ou from the First Hospital of Jilin University, the executive chairman of the conference, presided over the meeting and extended a warm welcome to all the participants.

Afterwards, the chairman of the conference, Professor Wu Depei of the First Affiliated Hospital of Soochow University, Professor Zhao Weilai of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, and Professor Li Jianyong of Jiangsu Provincial People's Hospital respectively delivered opening speeches.

Chairperson Wu Depei delivered a speech.
Young doctors are the future of the discipline.
This conference focuses on young people and can open up learning ideas and provide guidance for young doctors.

Dean Zhao Weilai delivered a speech.
The colleagues at the meeting are very excellent workers engaged in lymphocytic diseases.
We look forward to the joint efforts of everyone and cooperation with each other to enable the Lymphocytic Disease Group of the Chinese Medical Association Hematology Branch to be able to More progress has been made in diagnosis and treatment.

Director Li Jianyong delivered a speech.
He is very happy to participate in this conference.
Many big coffees will participate in the lectures and discussions of this conference.
It will be wonderful and I wish this conference a complete success.


Conference speech The first session of the academic lecture: Progress in the molecular pathology of highly aggressive B-cell lymphoma was presided over by Professor Zhou Xiaoge from Beijing Friendship Hospital and Professor Wang Yinping from Jilin University First Hospital.
Professor Huang Yuhua from Sun Yat-sen University Cancer Center said "Highly aggressive B Professor Huang Yuhua said that highly aggressive B-cell lymphoma has the characteristics of high proliferative activity.
MYC is a multifunctional transcription factor that plays an important role in tumorigenesis.
Highly aggressive B-cell lymphoma (including Burkitt lymphoma, double-hit and triple-hit lymphoma, plasmablastic lymphoma [PBL], etc.
) is also of great significance in the pathological diagnosis and treatment.

MYC-driven lymphoma targeted oncoprotein synthesis has shown good therapeutic effects in vivo and in vitro, providing a potential therapeutic strategy.

The study found that the classic DLBCL pathology marker molecules are not suitable for CNS DLBCL.
Therefore, Professor Huang Yuhua based on the mutation status of CD79b and PIM1, proposed the latest molecular taxonomy method, and divided PCNSL into CDP and nonCDP groups.

A follow-up study found that the CDP group had a longer survival time than the nonCDP group, which provided a new basis for the pathological diagnosis of CNS DLBCL.

Subsequently, Professor Yi Hongmei from Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Professor Jiang Yi from the Second Xiangya Hospital of Central South University participated in the discussion.

Professor Zhou Xiaoge and Professor Wang Yinping presided over the meeting.
Professor Huang Yuhua’s academic report.
Professor Yi Hongmei and Professor Jiang Yi participated in the discussion.
The second session: Progress in the diagnosis and treatment of diffuse large B-cell lymphoma.
Professor Daobin Zhou from Peking Union Medical College Hospital and Feng Feng from Nanfang Hospital of Guangzhou Southern Medical University Professor Ru served as the chair, and Professor Niu Ting from West China Hospital of Sichuan University gave a wonderful academic report on the progress of the diagnosis and treatment of diffuse large B-cell lymphoma.

Professor Niu Ting introduced that there are approximately 150,000 new large B-cell lymphoma patients worldwide each year, accounting for approximately 30% of all non-Hodgkin’s lymphoma cases.

More than 60% of patients can be cured by the R-CHOP immunochemotherapy regimen.

For patients who have failed first-line treatment, especially those with refractory diseases, the prognosis is still poor.

Researchers have also conducted a series of active research explorations.

Professor Niu Ting said that there are still many unresolved clinical problems in DLBCL.
With the advent of new molecular typing methods and targeted therapies, it is believed that the cure rate will become higher and higher.

At the end of this session, Professor Fan Lei from Jiangsu Provincial People's Hospital and Professor Zhao Donglu from Harbin Institute of Hematology and Tumor participated in the discussion.

Professor Niu Ting’s academic report Professor Fan Lei and Professor Zhao Donglu participated in the third session: Progress in the diagnosis and treatment of follicular lymphoma.
In the next session, Professor Wang Xin from Shandong Provincial Hospital and Professor Li Fei from the First Affiliated Hospital of Nanchang University hosted the discussion.
Professor Xu Bing from the First Affiliated Hospital of Xiamen University gave an academic report on "Progress in the Diagnosis and Treatment of Follicular Lymphoma".

The treatment of limited-stage follicular lymphoma (FL) is still mainly radiotherapy ± CD20 monoclonal antibody; in the treatment of advanced FL, R2, BR and R-CHOP regimens are firmly established, and the most suitable regimen should be selected according to the individual conditions of the patient .

In the refractory and recurrence stage, treatment options should also be selected according to the different individual conditions of patients.
Professor Xu Bing said that targeted therapy and immunotherapy are still research hotspots, but how to choose, sort and combine them still poses great challenges.

Finally, Professor Liu Yao from the Cancer Hospital of Chongqing University and Professor Yu Wenjuan from Zhejiang First Hospital participated in the discussion.

Professor Wang Xin and Professor Li Fei chaired the meeting.
Professor Xu Bing’s academic report.
Professor Liu Yao and Professor Yu Wenjuan participated in the discussion.
Session 4: Progress in the diagnosis and treatment of chronic lymphocytic leukemia.
Subsequently, Professor Wang Jingwen from Beijing Tongren Hospital of Capital Medical University and Zhou Fan from the Northern Theater General Hospital Professor Yi Shuhua from the Hospital of Hematology, Chinese Academy of Medical Sciences shared the diagnosis and treatment progress of chronic lymphocytic leukemia (CLL).

Professor Yi Shuhua said that with the advent of BTK inhibitors, the treatment of CLL has entered a new stage.

For the treatment of CLL, the combination of new and old drugs is an important choice at this stage, and the combination of new drugs and new drugs is the future research direction.

In addition, Professor Yi Shuhua also introduced the clinical trials currently being carried out by the Hematology Hospital of the Chinese Academy of Medical Sciences, hoping that everyone can recommend suitable patients to participate in the corresponding clinical trials, so as to benefit more patients.

Professor Huang Haiwen from the First Affiliated Hospital of Soochow University and Professor Wang Xiaobo from the Second Affiliated Hospital of Dalian Medical University participated in the discussion.

Professor Wang Jingwen and Professor Zhou Fan chaired the meeting.
Professor Yi Shuhua’s academic report.
Professor Huang Haiwen and Professor Wang Xiaobo participated in the discussion.
The fifth session: EBV-related lymphoproliferative diseases.
In this academic report, Professor Song Yongping from the Affiliated Tumor Hospital of Zhengzhou University and Soochow University Professor Jin Zhengming from the First Affiliated Hospital hosted, and Professor Wang Zhao from Beijing Friendship Hospital, Capital Medical University, shared the topic of "EBV-related Lymphocytic Proliferative Diseases".

Epstein-Barr virus-related T/NK cell lymphoproliferative diseases (EBV-T/NK-LPD) are a group of diseases with large differences in severity, ranging from reactive lymphoid tissue hyperplasia to malignant tumors.

Professor Wang Zhao said that EBV-T/NK-LPD currently lacks standard treatment options, and allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is still the only curable method at present.

There are still many problems in pathogenesis, diagnosis, and treatment that need to be solved urgently, and non-transplantation treatment options are still being explored.

Subsequently, Professor Wang Ye Ye from the First Affiliated Hospital of Harbin Medical University and Professor Cui Guohui from Union Hospital of Huazhong University of Science and Technology had a wonderful discussion on this topic.

Professor Song Yongping and Professor Jin Zhengming presided over the meeting.
Professor Wang Zhao’s academic report.
Professor Wang Ye Zi and Professor Cui Guohui participated in the discussion.
The sixth session: The progress of lymphoma CAR-T treatment.
In the last academic report, Professor Liang Aibin from Shanghai Tongji Hospital and China Medical University Professor Liu Zhuogang of Shengjing Hospital affiliated to the hospital served as the chairperson, and Professor Qian Wenbin from the Second Affiliated Hospital of Zhejiang University School of Medicine shared the topic of "Progress in Lymphoma CAR-T Treatment".

At present, CAR-T cell therapy has made good progress in the treatment of relapsed/refractory B-cell lymphoma, but about half of the patients still cannot benefit from CAR-T cell therapy.
Even if complete remission is achieved, about 20% Of patients will experience recurrence of the disease.

In order to further improve the effect of CAR-T therapy, domestic researchers have also made some improvements to CAR-T cells.
Professor Qian Wenbin said that the current development of domestic humanized CAR-T cell research leads the world.

In addition, improving the tumor microenvironment and reducing T cell exhaustion are important research directions in the future.

Finally, Professor Qian Wenbin said that CAR-T cell therapy combined with immune checkpoint inhibitors may also be a potential treatment strategy.

Subsequently, Professor Xu Pengpeng from Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Professor Guo Wei from the First Hospital of Jilin University participated in the discussion in this session.

Professor Liang Aibin and Professor Liu Zhuogang presided over the meeting.
Professor Qian Wenbin’s academic report.
Professor Xu Pengpeng and Professor Guo Wei participated in the discussion.
Professor Bai Ou said that the conference’s special lectures range from pathology to clinical practice, from standard treatment to new drug discovery, and from aggressive lymphatics.
From tumor to indolent lymphoma, as well as the progress of EBV virus infection and CAR-T cell therapy, the elite speakers shared research data and clinical experience.
The content is detailed, full of dry goods, and wonderful, which benefits everyone a lot and encourages everyone to be in the lymph Go to the future together on the road to tumor diagnosis and treatment.

This conference attracted the attention of many workers in the lymphoma field, with more than 2,300 online viewers, and it was a complete success.

Finally, Professor Bai Ou expressed his gratitude to the Lymphocytic Disease Group of the Hematology Branch of the Chinese Medical Association and the experts participating in the meeting and announced the successful conclusion of the meeting.

More than 2,300 viewers watched this conference online, "read the original text" and watch the replay